Obsidian Therapeutics OBX

Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered tumor infiltrating lymphocyte, or TIL, cell therapies for the treatment of patients with solid tumors. The company utilizes its proprietary cytoDRiVE™ platform to regulate protein function through drug responsive domains, or DRDs, enabling precise control of therapeutic proteins such as membrane-bound IL15, or mbIL15, in its cell therapies. Its lead product candidate, amsoki-cel™, is an autologous TIL cell therapy engineered to express pharmacologically regulatable mbIL15, designed to enhance tumor-killing activity while improving safety and enabling outpatient administration.

The company generates revenue through the development and potential commercialization of its product candidates, primarily amsoki-cel™, which is intended for the treatment of advanced melanoma and non-small cell lung cancer, or NSCLC. Revenue is expected to derive from product sales following regulatory approval, with additional potential income from licensing, collaborations, or partnerships involving its cytoDRiVE™ platform. The company currently has no commercial product sales and is focused on advancing its clinical programs to support future regulatory submissions.

The company operates through the following segments:

• Research and Development: This segment encompasses the discovery, preclinical development, and clinical advancement of the company’s product candidates, including amsoki-cel™ and earlier-stage cytoTIL™ therapies. It includes activities related to the cytoDRiVE™ platform, such as identifying and optimizing drug responsive domains, engineering mbIL15 constructs, and developing manufacturing processes. The segment also involves conducting clinical trials, including the ongoing Agni-01 multicenter study for amsoki-cel™ in melanoma and NSCLC, with data readouts expected in 2026 and 2027.
• Business Development, Finance, and General Management: This segment supports the company’s strategic initiatives, including securing funding, managing investor relations, overseeing financial operations, and guiding corporate strategy. It includes efforts to advance manufacturing capabilities through collaborations with contract development manufacturing organizations, or CDMOs, and planning for potential commercialization of amsoki-cel™ in the United States and other regions. The segment also handles intellectual property management, regulatory affairs, and external collaborations to expand the application of the cytoDRiVE™ platform beyond oncology.

Obsidian Therapeutics, Inc. operates in the competitive landscape of cell therapy for solid tumors, where it differentiates itself through its cytoDRiVE™ platform enabling regulated expression of mbIL15 in amsoki-cel™. The company faces competition from other TIL cell therapy providers such as Iovance Biotherapeutics Inc., which markets Amtagvi®, as well as companies developing CAR-T and TCR-T therapies for solid tumors. Its competitive advantages include a potentially superior safety profile with no treatment-related mortality observed in clinical trials, reduced reliance on toxic interleukin-2, outpatient-compatible low-dose lymphodepletion, and the ability to use minimally invasive core needle biopsies for tumor procurement.

The company’s customer base consists primarily of patients with advanced solid tumors, particularly those with melanoma and NSCLC who have progressed after immune checkpoint inhibitor therapy. These patients are typically treated in oncology centers and hospitals by specialists such as oncologists and immunotherapists. While specific customer names are not disclosed, the company serves individuals seeking treatment for refractory or resistant cancers through clinical trials and anticipates serving broader patient populations upon potential regulatory approval.